Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 6, 2017

Primary Completion Date

November 21, 2019

Study Completion Date

April 10, 2020

Conditions
Breast Cancer
Interventions
DRUG

Fulvestrant with Enzalutamide

500mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC) and 160mg of Enzalutamide will be given PO daily. Patients will receive a tumor biopsy at the start of treatment and 4 weeks after the start of treatment, with an optional 3rd biopsy at the end treatment.

Trial Locations (3)

38138

West Cancer Center, Germantown

80045

University of Colorado, Aurora

80124

Lone Tree Medical Center, Lone Tree

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

University of Colorado, Denver

OTHER

NCT02953860 - Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer | Biotech Hunter | Biotech Hunter